Establishing an osteosarcoma associated protein-protein interaction network to explore the pathogenesis of osteosarcoma

European Journal of Medical Research

Zheng-Dong Cai¹  Ying-Qi Hua¹  Bi-Yong Deng¹ 

[1] Department of Orthopedic Surgery, Shanghai Tenth people’s Hospital, Tongji University School of Medicine, No.301 Middle Yan-Chang Road, Zha-Bei District, Shanghai 200072, China

关键词: Pathway enrichment analysis;    Protein-protein interaction network;    Differentially expressed genes;    Osteosarcoma;   

Others  :  817712
DOI  :  10.1186/2047-783X-18-57

 received in 2013-06-19, accepted in 2013-11-25,  发布年份 2013

【 摘 要 】

Background

The aim of this study was to establish an osteosarcoma (OS) associated protein-protein interaction network and explore the pathogenesis of osteosarcoma.

Methods

The gene expression profile GSE9508 was downloaded from the Gene Expression Omnibus database, including five samples of non-malignant bone (the control), seven samples for non-metastatic patients (six of which were analyzed in duplicate), and 11 samples for metastatic patients (10 of which were analyzed in duplicate). Differentially expressed genes (DEGs) between osteosarcoma and control samples were identified by packages in R with the threshold of |logFC (fold change)| > 1 and false discovery rate < 0.05. Osprey software was used to construct the interaction network of DEGs, and genes at protein-protein interaction (PPI) nodes with high degrees were identified. The Database for Annotation, Visualization and Integrated Discovery and WebGestalt software were then used to perform functional annotation and pathway enrichment analyses for PPI networks, in which P < 0.05 was considered statistically significant.

Results

Compared to the control samples, the expressions of 42 and 341 genes were altered in non-metastatic OS and metastatic OS samples, respectively. A total of 15 significantly enriched functions were obtained with Gene Ontology analysis (P < 0.05). The DEGs were classified and significantly enriched in three pathways, including the tricarboxylic acid cycle, lysosome and axon guidance. Genes such as HRAS, IDH3A, ATP6ap1, ATP6V0D2, SEMA3F and SEMA3A were involved in the enriched pathways.

Conclusions

The hub genes from metastatic OS samples are not only bio-markers of OS, but also help to improve therapies for OS.

【 授权许可】

   
2013 Deng et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Ottaviani G, Jaffe N: The epidemiology of osteosarcoma. In Pediatric and Adolescent Osteosarcoma. Springer; 2010:3-13.
• [2]Brodey RS, Riser WH: Canine asteosarcoma: a clinicopathologic study of 194 cases. Clin Orthop Relat Res 1969, 62:54-64.
• [3]Bacci G, Picci P, Ferrari S, Ruggieri P, Casadei R, Tienghi A, Prever ABD, Gherlinzoni F, Mercuri M, Monti C: Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 1993, 72:3227-3238.
• [4]Bacci G, Mercuri M, Briccoli A, Ferrari S, Bertoni F, Donati D, Monti C, Zanoni A, Forni C, Manfrini M: Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Cancer 1997, 79:245-254.
• [5]Marina N, Gebhardt M, Teot L, Gorlick R: Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004, 9:422-441.
• [6]Lu X-Y, Lu Y, Zhao Y-J, Jaeweon K, Kang J, Xiao-Nan L, Ge G, Meyer R, Perlaky L, Hicks J: Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma. Mol Cancer Res 2008, 6:937-946.
• [7]Song B, Wang Y, Titmus MA, Botchkina G, Formentini A, Kornmann M, Ju J: Research Molecular Mechanism of Chemoresistance by miR-215 in Osteosarcoma and Colon Cancer Cells. 2010.
• [8]Laverdiere C, Hoang BH, Yang R, Sowers R, Qin J, Meyers PA, Huvos AG, Healey JH, Gorlick R: Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res 2005, 11:2561-2567.
• [9]Luu HH, Zhou L, Haydon RC, Deyrup AT, Montag AG, Huo D, Heck R, Heizmann CW, Peabody TD, Simon MA: Increased expression of S100A6 is associated with decreased metastasis and inhibition of cell migration and anchorage independent growth in human osteosarcoma. Cancer Lett 2005, 229:135-148.
• [10]Kang HG, Kim HS, Kim KJ, Oh JH, Lee MR, Seol SM, Han I: RECK expression in osteosarcoma: correlation with matrix metalloproteinases activation and tumor invasiveness. Journal Orthop Res 2007, 25:696-702.
• [11]Fisher JL, Mackie PS, Howard ML, Zhou H, Choong PFM: The expression of the urokinase plasminogen activator system in metastatic murine osteosarcoma: an in vivo mouse model. Clin Cancer Res 2001, 7:1654-1660.
• [12]Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, Yeung C, Trepel J, Meltzer P, Helman L: Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res 2001, 61:3750-3759.
• [13]Endo-Munoz L, Cumming A, Rickwood D, Wilson D, Cueva C, Ng C, Strutton G, Cassady AI, Evdokiou A, Sommerville S: Loss of osteoclasts contributes to development of osteosarcoma pulmonary metastases. Cancer Res 2010, 70:7063-7072.
• [14]Troyanskaya O, Cantor M, Sherlock G, Brown P, Hastie T, Tibshirani R, Botstein D, Altman RB: Missing value estimation methods for DNA microarrays. Bioinformatics 2001, 17:520-525.
• [15]Fujita A, Sato J, Rodrigues L, Ferreira C, Sogayar M: Evaluating different methods of microarray data normalization. BMC Bioinformatics 2006, 7:469. BioMed Central Full Text
• [16]Smyth GK: Limma: linear models for microarray data. In Bioinformatics and Computational Biology Solutions using R and Bioconductor. Springer; 2005:397-420.
• [17]Dudoit S, Shaffer JP, Boldrick JC: Multiple hypothesis testing in microarray experiments. Stat Sci 2003, 71-103.
• [18]Breitkreutz B-J, Stark C, Tyers M: The GRID: the general repository for interaction datasets. Genome Biol 2003, 4:R23. BioMed Central Full Text
• [19]Stark C, Breitkreutz B-J, Reguly T, Boucher L, Breitkreutz A, Tyers M: BioGRID: a general repository for interaction datasets. Nucleic acids research 2006, 34:D535-D539.
• [20]Willis RC, Hogue CW: Searching, viewing, and visualizing data in the Biomolecular Interaction Network Database (BIND). Curr Protoc Bioinformatics 2006, 8.9:1-8. 9. 30
• [21]Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al.: Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000, 25:25-29.
• [22]Sherman BT, Lempicki RA: Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic acids research 2009, 37:1-13.
• [23]Yu G, Wang LG, Han Y, He QY: ClusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 2012, 16:284-287.
• [24]da Huang W, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2008, 4:44-57.
• [25]Zhang B, Kirov S, Snoddy J: WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 2005, 33:W741-W748.
• [26]Duncan D, Prodduturi N, Zhang B: WebGestalt2: an updated and expanded version of the Web-based Gene Set Analysis Toolkit. BMC Bioinformatics 2010, 11:P10. BioMed Central Full Text
• [27]Mullen AR, Wheaton WW, Jin ES, Chen P-H, Sullivan LB, Cheng T, Yang Y, Linehan WM, Chandel NS, DeBerardinis RJ: Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 2011, 481:385-388.
• [28]Bihani T, Mason DX, Jackson T, Chen SC, Boettner B, Lin AW: Differential oncogenic Ras signaling and senescence in tumor cells. Cell Cycle 2004, 3:1199-1205.
• [29]Yang DQ, Feng S, Chen W, Zhao H, Paulson C, Li YP: V‒ATPase subunit ATP6AP1 (Ac45) regulates osteoclast differentiation, extracellular acidification, lysosomal trafficking, and protease exocytosis in osteoclast‒mediated bone resorption. J Bone Miner Res 2012, 27:1695-1707.
• [30]Kim T, Ha H-I, Kim N, Yi O, Lee SH, Choi Y: Adrm1 interacts with Atp6v0d2 and regulates osteoclast differentiation. Biochem Biophys Res Commun 2009, 390:585-590.
• [31]Broadhead ML, Clark JC, Dass CR, Choong PF, Myers DE: Therapeutic targeting of osteoclast function and pathways. Expert Opin Ther Targets 2011, 15:169-181.
• [32]Kikuta J, Ishii M: Osteoclast migration, differentiation and function: novel therapeutic targets for rheumatic diseases. Rheumatology 2013, 52:226-234.
• [33]Jensen ED, Pham L, Billington CJ, Espe K, Carlson AE, Westendorf JJ, Petryk A, Gopalakrishnan R, Mansky K: Bone morphogenic protein 2 directly enhances differentiation of murine osteoclast precursors. J Cell Biochem 2010, 109:672-682.
• [34]Murthy MB: Osteoimmunology - unleashing the concepts. J Indian Soc Periodontol 2011, 15:190.
• [35]Bielenberg DR, Klagsbrun M: Targeting endothelial and tumor cells with semaphorins. Cancer Metastasis Rev 2007, 26:421-431.
• [36]Kawakami T, Tokunaga T, Hatanaka H, Kijima H, Yamazaki H, Abe Y, Osamura Y, Inoue H, Ueyama Y, Nakamura M: Neuropilin 1 and neuropilin 2 co‒expression is significantly correlated with increased vascularity and poor prognosis in nonsmall cell lung carcinoma. Cancer 2002, 95:2196-2201.
• [37]Narazaki M, Tosato G: Tumor cell populations differ in angiogenic activity: a model system for spontaneous angiogenic switch can tell us why. J Natl Cancer Inst 2006, 98:294-295.
• [38]Handa A, Tokunaga T, Tsuchida T, Lee YH, Kijima H, Yamazaki H, Ueyama Y, Fukuda H, Nakamura M: Neuropilin-2 expression affects the increased vascularization and is a prognostic factor in osteosarcoma. Int J Oncol 2000, 17:291-295.
• [39]Mori K, Berreur M, Blanchard F, Chevalier C, Guisle-Marsollier I, Masson M, Rédini F, Heymann D: Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. Oncology Rep 2007, 18:1365-1371.